An Open-label Proof-of-concept Study With a Double-masked, Dose-ranging Component to Assess the Effects of AIN457 in Patients With Noninfectious Uveitis
Patients are being enrolled in the uveitis clinical trial called the Novartis AIN457 study, that are designed to investigate the safety and effectiveness of an investigational biological medication for people with active or inactive non-infectious intermediate, posterior, or pan-uveitis.
Patients enrolled in this study will have the following outcomes measured:
Dr. C. Micheal Samson, Uveitis Specialist and Principal Investigator of this study can determine if you are eligible.
This is a fully funded trial. All research related procedures and medication will be at no cost to the patient.
To see if you qualify and to make an appointment for the Novartis AIN457 study, please call Katy Tai, Clinical Research Manager at 212-979-4251.